Welcome to our dedicated page for EUDA Health Holdings news (Ticker: EUDA), a resource for investors and traders seeking the latest updates and insights on EUDA Health Holdings stock.
EUDA Health Holdings Limited reports developments across non-invasive and preventive healthcare in Asia, with a focus on Singapore, Malaysia and China. Company updates include longevity and personalized healthcare services, regenerative medicine access, stem cell extraction and cryogenic storage, and commercial arrangements for selected cellular immunotherapies, including TCR-T-related therapies supplied through Shenzhen Inno Immune.
EUDA announcements also cover public-company capital actions and Nasdaq listing matters. Recent corporate developments include ordinary-share adjustments, warrant amendments and cancellations, registered share offerings, and governance actions tied to its capital structure as a Nasdaq-listed foreign private issuer.
Summary not available.
Summary not available.
EUDA Health Holdings Limited (NASDAQ: EUDA, EUDAW), a Singapore-based health technology company, announced it received a delinquency notification from Nasdaq on April 5, 2023, due to its failure to file the Annual Report on Form 10-K for the fiscal year ending December 31, 2022. The company has 60 days to submit a compliance plan. If accepted, it could receive up to 180 days to file the report. Management is working to complete the necessary information but needs additional time for final audits. The delinquency notice does not immediately impact the trading of EUDA's common stock, which remains listed on Nasdaq.